Sutro Biopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sutro Biopharma, Inc. (Nasdaq: STRO) on December 1, 2020, covering events occurring on November 30, 2020. The Company is a biopharmaceutical firm incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and compensation matters.
Material Changes
On November 30, 2020, the Board of Directors appointed Jon Marc Wigginton, M.D., as a Class I director and member of the Science and Technology Committee, effective immediately.
Compensation and Governance Details
- Retainer Fees: Dr. Wigginton will receive a pro rata portion of the $40,000 annual director retainer and a pro rata portion of the $5,000 annual Science and Technology Committee retainer for the remainder of the year.
- Stock Option Grant: The Board granted Dr. Wigginton an option to purchase 24,000 shares of common stock. The exercise price equals the closing sale price on November 30, 2020. The option vests monthly over three years, contingent on continued service.
- Indemnification: The Company entered into its standard form of indemnification agreement with Dr. Wigginton.
- Relationships: There are no family relationships between Dr. Wigginton and other directors or officers, and no undisclosed material interests in transactions.
Outlook and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on business risks, or unusual items.
Investor Verification Checklist
- Verify the closing stock price on November 30, 2020, to determine the exercise price of the 24,000 share option grant.
- Review the Company's existing compensation policy for non-employee directors to confirm the pro rata calculation methodology.
- Confirm Dr. Wigginton's continued service status to ensure vesting conditions are met.